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Obtaining atomistic resolution of drug unbinding from a protein is a much sought-after experimental and com-
putational challenge. We report the unbinding dynamics of the anticancer drug dasatinib from c-Src kinase in full
atomistic resolution using enhanced sampling molecular dynamics simulations. We obtain multiple unbinding
trajectories and determine a residence time in agreement with experiments. We observe coupled protein-water
movement through multiple metastable intermediates. The water molecules form a hydrogen bond bridge, elon-
gating a specific, evolutionarily preserved salt bridge and enabling conformation changes essential to ligand un-
binding. This water insertion in the salt bridge acts as a molecular switch that controls unbinding. Our findings
provide a mechanistic rationale for why it might be difficult to engineer drugs targeting certain specific c-Src
kinase conformations to have longer residence times.D
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Traditional computational drug design has been based on the optimi-
zation of the binding affinity of a drug for a target. However, it is be-
coming increasingly recognized that the efficacy of a drug is determined
not only by its equilibriumbinding affinity but also by its residence time
in the target protein (1, 2). Thus, effective drug design should not be
exclusively based on the thermodynamic binding affinity, and it
becomes desirable to extend the traditional design strategies to incor-
porate calculation of the drug-target lifetime (often expressed through
its inverse, the off-rate koff). Although experimental techniques can
directly measure the unbinding time, the unbinding dynamics of a
drug is much more than just a number. Along with quantifying the
residence time, it is important to understand the molecular determi-
nants of unbinding and how they give rise to dissociation pathways
and barriers. These determinants include, but are not limited to, key
protein-drug and protein-protein interactions, conformational states
of the protein, ligand flexibility, and solvation effects (1–4). Armed
with an atomistic resolution understanding of the role played by these
determinants in the unbinding dynamics, one can then imagine pro-
posing structural modifications to a ligand that would lead to ideally
desired longer residence times.
Here, we gain atomic-level insight into the unbinding mechanisms
of the anticancer drug dasatinib from the kinase c-Src by performing
extensive fully atomistic molecular dynamics (MD) simulations. c-Src
is a nonreceptor cytoplasmic tyrosine kinase that is involved in a mul-
titude of cell signaling activities and whose heightened activity has
been linked to the progression of a variety of cancers, including those
in the colon, liver, lung, and pancreas (5). Dasatinib (sold under the
trade name Sprycel by Bristol-Myers Squibb) is a U.S. Food and Drug
Administration–approved drug that is used to treat patients with
chronicmyelogenous leukemia and other related ailments by blocking
c-Src as well as Abl kinases. Using fully atomistic simulations to un-
derstand the detailed basis of how dasatinib unbinds arguably could
have profound implications for designing tailored drugs with desired
residence times. However, the reported residence times of dasatinib,
and ofmost successful drugs in general, arewell into seconds or slower,which is far beyond the reach of atomistic simulationswithout the use of
carefully designed enhanced sampling methods (6–9). As such, in this
work, we use an enhanced sampling method called “infrequent meta-
dynamics” (see Materials and Methods) that accelerates unbinding to
make it computationally tractable yet allows the recovery of unbiased
kinetic information, including pathways and time scales. This method
has been successfully used to study biophysical dynamics in a variety of
systems (6, 10–13) and is ideally suited for the problem at hand.
Here, we obtain 12 independent unbinding trajectories that begin
from the bound x-ray structure for dasatinib with c-Src kinase [PDB
(Protein Data Bank) 3G5D] and culminate when the ligand is either
fully solvated or diffusing on the surface of the protein far from the
binding site. Our simulations show that the unbinding of dasatinib from
c-Src kinase proceeds throughmultiple intermediate stable states, facili-
tated by a fluctuating protein and aided by movement of water mole-
cules that modulate the disruption of shielded protein-protein and
protein-drug interactions.We quantify the lifetimes of these intermedi-
ates (ranging from fractions of milliseconds to seconds) and identify
two broad classes of slow steps in the unbinding process. The first slow
step involves an initial hydration of the binding pocket but with the lig-
and itself relatively stationary. This event is coupled with a temporary
disruption of a key evolutionarily preserved Glu-Lys salt bridge interac-
tion (14), which becomes water-mediated and effectively acts like amo-
lecular switch controlling the onset of unbinding. When distorted, this
salt bridge, which is considered as a hallmark of an activated kinase
when fully formed, creates space for further entry of water molecules
into the binding pocket. In the second and even slower step, assisted
by the water molecules now present in the binding pocket, the drug
breaks its primary interactions with the kinase residues and then finally
exits it. Typically, after the drug exits, the aforementioned water mole-
cules also leave the pocket, and theGlu-Lys salt bridge reforms, recover-
ing the x-ray pose. The drug then diffuses in the solvent or on the
surface of the protein, moving through a domain of attractive surface
spots. Here, we do not explore the time scales of this diffusion but in-
stead focus on the residence time of the drug in the primary binding
pocket. It is possible that these attractive spots on the surface that we
identified could either be alternate binding locations or have allosteric
effects on the binding to the primary pocket. Future work will consider
these very relevant questions.
We were able to calculate a residence time that agrees with re-
ported experimental measurements and determine mechanistic1 of 8
SC I ENCE ADVANCES | R E S EARCH ART I C L Efeatures pertaining to the rate-limiting steps in the unbinding of dasa-
tinib that also agree with experiments. This atomistic insight sheds light
on previously unexplained experimental observations (15), such as why
the targeting of certain c-Src kinase conformational forms might be fu-
tile for engineering desired increased drug residence times (16). Our
work also provides direct evidence that water is not just a spectator sol-
vent in drug unbinding but a very active participant (17–19). Our results
mark a significant step forward in the ability to calculate drug unbinding
pathways and rates with statistical reliability and to obtain a detailed
understanding of the complex nature of drug unbinding from an im-
portant target for various diseases, the c-Src kinases. o
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The enhanced sampling technique used in this work, metadynamics
(20), is a biasing procedure whereby periodically depositing bias as a
function of carefully chosen collective variables (CVs), the system is
assisted in moving across high-energy barriers that would ordinarily
be difficult to escape. Traditionally, the final outcome of this biasing
procedure is the unbiased probability distribution of the system, which
can be obtained directly by using Eq. 4 (Materials and Methods) or
through a reweighting procedure (20, 21). Independent of the free
energy estimate, one can also obtain kinetic rate constants through
the calculation of an acceleration factor, which directly gives a speed-
up in time achieved through metadynamics, assuming that certain
important conditions have been met (see Materials and Methods and
Eq. 1) (22, 23). One of the key conditions is that the bias should have
been deposited infrequently enough to leave the transition states be-
tween stable states untouched. This can be done if the underlying dy-
namical problem is characterized by a few sharp and dominant free
energy barriers. The time scales reweighted from metadynamics can
then be trusted if they conform to time-homogeneous Poisson statistics
(seeMaterials andMethods).We can expect to use this self-consistency
criterion here to verify the accuracy of the accelerated time scales be-
cause ligand unbinding has been shown in various previous experimen-
tal and numerical studies to conform to the aforementioned energy
landscape picture with a small number of prominent barriers and short
transition path times (24–28).
Here, we perform 12 independent metadynamics runs, all of which
result in unbinding of the ligand. These give a directmeasurement of the
residence time equaling 21 ± 10 s, which agrees with reported experi-
mental observations lying in the range of 18 s [using the values Kd (dis-
sociation constant) = 0.011 mM and kon = 5 s
−1 mM−1 and the relation
koff = konKd; residence time = 1/koff (29, 30)] to 900 s (15) (coming from
the fluorescent-labeled analog of dasatinib). We performed the calcula-
tions using the OPLS all-atom force field and TIP4P water models
(31, 32) and also validated the results using the AMBER all-atom force
field (33) with TIP4P water to check for qualitative consistency of the
key features (see the SupplementaryMaterials). Note that our measure-
ment of koff in this work as well as the experimental measurement of
Kwarcinski et al. (15) are direct and do not assume the relation koff =
konKd. However, if we take the liberty of using this relation along with
the experimental measured value of Kd, our measured koff corresponds
to kon = 4.3 s
−1mM −1, which is in marked and possibly fortuitous agree-
ment with the experimental measurement (kon = 5 s
−1mM −1) (30). Pre-
vious computational studies on this system have been semiquantitative
at best because of insufficient sampling but have obtained kon in a simi-
lar order of magnitude (30, 34).Tiwary, Mondal, Berne, Sci. Adv. 2017;3 : e1700014 31 May 2017Here, the metadynamics runs were performed by gradually biasing
two CVs, the distance d of the drug to the ligand and the solvation state
w of the binding pocket (see Materials and Methods for details). Our
particular choice of CVs for this system was motivated by reported
experiments and previous computer simulations of protein-ligand
systems [including that in this work (30, 34)], which suggest that both
the ligand-protein distance and the hydration of the binding pocket play
prominent roles in the unbinding process. In the Supplementary
Materials, we provide statistical analyses of the unbinding times ob-
tained. The Poisson distribution of the unbinding time scales obtained
by biasing theCVs d andw gives us some confidence that, at least for the
system in this work, these two CVs do suffice to capture the slow dy-
namics relevant to the unbinding of dasatinib, and any other slow varia-
bles relevant to unbinding are nonorthogonal to these two. In future
work on drug unbinding, we intend to use the methods of Tiwary
and Berne (35), which was shown to be useful for CV selection with
minimal preknowledge of the system. In the study of Tiwary and Berne
(36), we also consider the question of how diffusional anisotropy in the
CVs can be incorporated into this framework. In the Supplementary
Materials, we provide further detailed validation of a master equation
built from our simulations, which adds to our confidence that any other
slow variables for unbinding are not orthogonal to d and w.
Approximate free energy surface and stable intermediates
In Fig. 1, we provide the approximate free energy surface (FES) (defined
in Eq. 4 inMaterials andMethods) as a function of d andw, obtained by
averaging the various unbinding runs (see the SupplementaryMaterials
for theory regarding relation between bias and equilibrium free energy
in metadynamics). To converge FES reported in this work in terms of
the relative stability of basins, one would need frequent bias deposition,
which is not our aimhere, andwe use the FES averaged from the various
infrequent biasing runs using Eq. 4 only to establish the approximate
locations of the various stable states and draw useful information about
the existence of metastable intermediates from the topology of this FES.
Also note that at no point dowemake use of the free energymagnitudes
to obtain the time scales or rate constants. This is done through the cal-
culation of the acceleration factor (Eq. 1 in Materials and Methods),
which does not need any estimates of the free energy. Because we have
already demonstrated that using d and w can capture relevant slow
motions in the unbinding, we do not need amore sophisticated full-atom
clustering scheme for the purpose of demarcating stable intermediates.
The main features of this FES are six basins or stable states such that
the barrier between them is at least 3kBT. There is nothing special about
this particular choice of this parameter for demarcating the stable states.
A higher thresholdwould lead to amodel with less number of states and
thus less information, whereas a lower number would have more de-
tailed information but also larger errors in the sampling of transition
rates between the different states. Any choice in the end has to be exam-
ined through self-consistency tests, which we describe here and in the
Supplementary Materials. We mark respective boundaries near the
transition regions between the states, as was done, for instance, by
Swope et al. (37). By counting transition rates between these stable
basins, we set up a master equation for the unbinding dynamics, with
absorbing boundary conditions in state 6 (unbound state). By solving for
the slowest eigenvalues of the transfermatrix (detailed in Fig. 2 and in the
Supplementary Materials), we get an estimate of the rate-determining
steps in the full unbinding dynamics reported in the previous section.
Note that in no way are we implying that this classification is the only
one consistent with the unbinding dynamics—the problem of finding2 of 8





 Fig. 1. Metastable intermediates, key residues, and interactions relevant to the unbinding of dasatinib from c-Src kinase, alongwith the associated FES as a function
of ligand-bindingpocketdistance d (in nanometers) andhydration state of bindingpocketw. Energy is in units of kcal/mol, with contours drawn every 0.5 kcal/mol. Various
relevant residues alongwithwatermolecules that enter the protein have beenmarked, and dasatinib is shownusing theball and stickmodel. State 6 (unbound state) is illustrated
separately in Fig. 4. See Results for detailed descriptions of the defining interactions in every state. o
n
 January 16, 2018
iencem
ag.org/Fig. 2. The complex network of state-to-state transitions for dasatinib as it moves from bound to unbound state, with rate constants in s−1 and various residence
times. See Fig. 1 for definition of the various states. The radii of circles for various states are approximately logarithmically proportional to their respective residence times. The full
rate constant matrix is provided in the Supplementary Materials.Tiwary, Mondal, Berne, Sci. Adv. 2017;3 : e1700014 31 May 2017 3 of 8
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 a coarse Markovian model that fits higher-resolution observations has
many solutions, and the analysis we present is simply one Markovian
classification, consistent with all observations at hand. In the Supplemen-
tary Materials, we present a detailed robustness analysis of the master
equation with respect to recrossings between stable states.
Molecular characteristics of various stable intermediates
The various stable intermediates involved in the unbinding of dasatinib
are illustrated alongside the FES in Fig. 1, and a schematic summarizing
the complex network of transitions between these states is provided in
Fig. 2. The lifetimes reported here are obtained by summing the times
spent in the respective stable states in Fig. 1. Detailed analyses of these
alongwith error estimates are provided in the SupplementaryMaterials.
State 1 is the x-ray–bound pose, whose lifetime we found to be
around 8 s. The important stabilizing interactions in this pose are be-
tween the ligand and the residues Thr74, Glu75, andMet77 in the protein,
as documented in various other published works (4, 29). Also note the
salt bridge between Lys36 and Glu46, which is evolutionarily preserved
across the kinome and is critical for kinase functioning.
The next stable state is state 2, with an average lifetime of around 1 s.
Themost distinct characteristic of this state is that the Lys36-Glu46 direct
interaction is broken and is instead water-mediated, with the aC helix
rotated outward, relative to state 1. Glu46 engages in water-mediated
interactions with either of the two arginine residues, Arg121 or Arg145,
which play a role in the transition of the kinase from active to inactive
(38). In these first two states, there is relatively minimal movement of
the ligand with respect to the protein, and the long residence times can
be explained by the key interactions being preserved.
State 3 has a lifetime of 4ms and involves further entry of watermol-
ecules into the binding pocket space opened up by the rotation of the
aC helix. Most notably, one of these water molecules now helps break
the shielded hydrogen bond between the buried Thr74 residue and da-
satinib (Fig. 1). As per our classification, there is a range of positions of
Glu46 in this state, where it can continue to interact with the arginine of
state 2 directly or through water mediation. This state, which is a nec-
essary and long-lived intermediate for dasatinib unbinding, is very close
in root mean square deviation (RMSD) to the aC helix–out structure
reported for c-Src kinase (PDB 4YBK) in complex with certain aC
helix–out binders (see Fig. 3). The activation loop displayed high flex-
ibility in our simulations while staying unfolded through the entirety of
all our runs. Note that theDFGmotif (residues 140 to 142) of the kinase
stays in the so-called “in” state.
Once the deeply buried hydrogen bond between dasatinib and the
protein is broken in state 3, the ligand becomes more mobile, as can be
seen from the elongation of basin 3 in the FES in Fig. 1. States 4 and 5
have lifetimes of 71 and 100 ms, respectively. They correspond to the
gradual breaking of the interactions between the ligand and the residues
Glu75 and Met77, again aided by water molecules that entered the
binding pocket. After exiting state 5, the drug diffuses either in the sol-
vent or on the surface of the protein by moving through a network of
interconnected domains, which we illustrate in Fig. 4. These domains
are in good qualitative agreement with the sites observed as the ligand
binds in unbiased binding simulations reported by Shan et al. (30).
Here, we do not characterize in detail the time scales for surface diffu-
sion, but from our runs, it appeared (at least qualitatively) that the time
scales were shorter by several orders of magnitude than the residence
time in the primary binding pocket. This is further supported by the
observation that even for surface sites located in roughly the same
region of the protein, the stabilizing interactions were not unique andTiwary, Mondal, Berne, Sci. Adv. 2017;3 : e1700014 31 May 2017changed from run to run. The small residence times in these surface
regions are probably due to the solvent-exposed nature of these regions
and their accessibility to water. An accurate characterization of the time
scales of the surface diffusion is beyond the scope of the infrequent me-
tadynamics method used in this work but has been attempted in the
past using other methods (34). Furthermore, it has also been documen-
ted that many force fields display a systematic bias toward increased
hydrophobic interactions that could possibly lead to spurious compac-
tion of unfolded proteins and systematic deviations in solvation free en-
ergies (39). An accurate study of the surface diffusionwould also need to
take this complication into account.
What are the slow and rate-limiting steps in the
unbinding process?
As summarized in Fig. 2, the unbinding of dasatinib is a fairly concerted
process that involvesmoving through the various stable states described
in the previous subsection and is reminiscent of the induced-fit mech-
anism described, for instance, by Copeland (1, 40). Upon solving for the
eigenvalues of the associated master equation, we identify two key slowFig. 3. Various protein structures aligned using the full protein’s heavy atoms,
showing the rotation of the aC helix and of the glutamic acid residue (Glu46 in
PDB 3G5D). Orange represents equilibrated aC helix–in structure, red is the aC helix–
out structure (or state 3 in Fig. 1) obtained from our runs, and blue is the aC helix–out
structure directly from the PDB database (PDB 4YBK) as reported by Kwarcinski et al.
(15). Note how theaC helices in the two out structures overlap fairly well and especially
how the glutamic residue is displaced almost identically in a roughly orthogonal direc-
tion to what it had in the aC helix–in structure. The stabilizing interaction between
residues Arg121 and Glu46 is also illustrated, along with the disordered activation loop
in purple. The underlying base structure is a representative aC helix–out structure ob-
tained from our runs. The reported structure (PDB 3G5D) in the protein database has
missing residues after the end of the helix, and as such, we do not include them in the
comparison here.4 of 8
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 steps in the network of steps (fig. S1B). The rate-limiting step involves
moving from states 3, 4, and 5 to 6, that is, the movement of the drug
accompanied with the breaking of the interactions between the drug
and the Glu75 andMet77 residues in a configuration where the aC helix
is already rotated. The second slow step, which is around seven times
faster than the true rate-limiting step but always happens before the sec-
ond step, is the rotation of the aC helix–out configuration from state
1 to 2, through coupled protein-water movements but with the drug
itself staying stationary. In this step, because the Lys36-Glu46 direct in-
teraction is broken (Fig. 3), the outward movement of Glu46 creates
space for water molecules to freely move in and out of the protein. Be-
cause we obtained the same qualitative unbinding mechanism using a
different classical force field, our confidence in this proposed mecha-
nism is strengthened (see the Supplementary Materials). However, er-
roneous stabilization of salt bridge strength could still be amore generic
force field artifact and will be investigated in future work.
The above observation is a crucial finding because it demonstrates
that a drug that binds to the aC helix–out conformation will not nec-
essarily have a longer residence time than a drug that binds to the true
aC helix–in configuration because even the latter has to move through
the aC helix–out configuration; moreover, the rate-limiting step comes
into play only after this conformation has been attained. That is, theTiwary, Mondal, Berne, Sci. Adv. 2017;3 : e1700014 31 May 2017Lys36-Glu46 salt bridge functions as a molecular switch that must be
“on” for the drug unbinding to progress. Designing drugs that target
kinase conformations with this switch already on might at best lead
to similar, if not shorter, residence times. Our findings are well sup-
ported by recent experimental measurements (15) where this was
found to be the case: Dasatinib had a very similar residence time
in c-Src kinase compared to a ligand that bound to c-Src kinase in
its aC helix–out configuration. In Fig. 3, we provide an overlay of the
latter configuration with our state 3 to demonstrate that they are very
similar. It will be interesting to see whether this same reasoning ap-
plies to other kinases, which adapt both the aC helix–in and aC
helix–out conformations.
Note that themolecular switchmechanismdescribed onlywhere the
Glu-Lys salt bridge distorts and where water enters the binding pocket
and does not indicate which is the cause and which is the effect: that is,
whether the salt bridge distortion leads to the entry of water molecules
or the water entry causes the salt bridge to distort. One way to settle this
question would be to start independent MD runs from a configuration
where water molecules had entered the pocket but the Lys36-Glu46 di-
rect interaction was still preserved, applying the static bias until this
point and adding no further bias after this point. However, given the
high–free energy barrier of the event, it might be very tricky to draw
statistically reliable information from this procedure. A more quantita-
tively robust approach to settling this question, which will be the subject
of future work, would be through the use of the algorithm spectral gap
optimization of order parameters (35), which allows distinguishing be-
tween driven versus driving variables.DISCUSSION
Here, we have studied in detail the unbinding dynamics of the anti-
cancer drug dasatinib from c-Src kinase. By collecting statistics over
multiple unbinding trajectories, we obtain a residence time in marked
agreement with the experimental measurements. It is possible that our
residence time estimates are slightly underestimated because of the ne-
glect of diffusive parts of the trajectory once the ligand is on the surface
of the protein. Apart from a quantitative agreement in residence times,
we also obtain a descriptive understanding of the pathways of unbind-
ing, where coupled protein-watermovement controls and facilitates the
unbinding of the drug, and an evolutionarily preserved salt bridge acts
like a molecular switch. This mechanism has been previously proposed
for slow unbinding systems, such as biotin-streptavidin (24, 25, 28),
where it was found that water entry coupledwith rupture of a salt bridge
is a necessary but insufficient step for unbinding. In our case, this salt
bridge comes from the aC helix, which is not entirely surprising given
that this helix is flexible across a variety of kinases (14, 38). The errors in
classical force fields could have significant effects on any such findings.
For instance, the OPLS force field, as used in this work, overestimates
the strength of salt bridges (41), such as the one we discuss here. How-
ever, the fact that we obtain the same qualitative mechanism with an-
other force field gives us confidence in our findings. Furthermore, the
ability to do these detailed kinetics calculations with mechanisms and
rate constants comparable to other experiments should also serve as a
tool in the endeavor to improve force fields.
Our work has at least two obvious pharmacological implications.
First, although hydration of the binding pocket and of the ligand is im-
portant in unbinding, our work shows exactly when and where on the
unbinding pathway the hydration happens and what roles it plays. Al-
though, strictly speaking, the hydration of the binding pocket is aFig. 4. An interconnected network of domains through which dasatinib moves
once unbound from the primary binding pocket (that is, d > 1.8 nm; see Fig. 1),
clearly demonstrating the presence of surface attractive spots. Here, various da-
satinib snapshots from the unbinding trajectory satisfying d >1.8 nm are marked in
purple on the protein (colored by residue name), which for illustrative purposes is kept
in the bound pose, and the surface of the protein is represented in gray.5 of 8
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 slightly faster step than the movement of dasatinib, we find that the
hydration step is the first slow step, and the associated barrier must be
surmounted before anything else can happen. Thus, one way to engi-
neer drugs with longer residence times that do not depend on specific
ligand-pocket interactionswould be to focus on controllingwater access
to the binding pocket.
Second, it explains and quantifies the role played by the aChelix and
the evolutionarily preserved Lys-Glu salt bridge as amolecular switch in
unbinding, helping us to understand the recent observation that drugs
binding to aC helix–out kinase conformations have similar residence
times as drugs binding to aC helix–in conformations. This understand-
ing has obvious pharmacological implications and, if verified for other
kinases, could be of considerable use in drug design by indicating that
slow off rates are not an inherent feature of aC helix–out unbinders, as
also noted in the experiments of Kwarcinski et al. (15). For instance,
extensive efforts have been made to design conformationally selective
kinase inhibitors, following the huge success of Gleevec (imatinib, No-
vartis) (42), which binds only to a very specific conformation (43). Our
work provides preliminary hints that chasing after specific kinase con-
formations might be rather futile from the perspective of tailoring
residence times. However, given that ligand unbinding involves passing
through the aC helix–out state, a better strategy to engineer drugs with
long residence times would be to block the accessibility of this state.
Given our identification of the slow steps in unbinding, we canmake
forward-looking suggestions that would be directly verifiable in ex-
periments and, if validated, could serve as general guiding principles
for engineering related drugs with long residence times. For instance,
it should be possible to introduce mutations in the aC helix itself or
in parts of the kinase domain that engage with the aC helix that restrict
the movement of the aC helix but do not disturb the key stabilizing
interactions in the bound dasatinib configuration.We expect this inter-
vention to have minimal effect on the Kd but an order of magnitude
effect on koff and possibly kon. Differences between how koff and kon
are affected would also serve as evidence for the asymmetrical nature
of binding/unbinding. Similar slowing down of the unbinding should
be expected by substituting D2O for H2O in the solvent.
We realize that the residence time of seconds we have achieved in
this work, although it represents a step forward for atomistic simula-
tions, can still be short of the desirable time scales for many practical
applications, when the target residence time exceeds the pharmaco-
kinetic half-life of the drug in systemic circulation (a time scale of tens
of minutes, hours, or even days) (1). That said, our current work marks
an ambitious and potential step toward mapping the unbinding mech-
anisms of various drugs from kinases and other proteins with all-atom
insight. Many successful kinase inhibitors on the market, which are
often only one of a kind, are distinguished among other things by their
long residence times in selected kinases, for example, Iclusig (ponatinib,
Ariad Pharmaceuticals), which has long residence times even in the dif-
ficult case of tyrosine kinases with mutated gatekeeper residues (44),
quite possibly a reason why it is one of the only available drugs to treat
certain rare blood and bonemarrow diseases. Although the calculations
performed in this work are still computationally too expensive to be ap-
plied to a series of ligands against a series of mutated proteins, the
continued improvements in computing power and force fields, coupled
with the development of reliable enhanced sampling methodologies
such as but not limited to those presented by Tiwary and Berne (35),
makes us optimistic that we will soon be able to speed up these calcula-
tions, enough to achieve the design of drugs with tailored residence
times in specific proteins, directly guided by atomistic simulations.Tiwary, Mondal, Berne, Sci. Adv. 2017;3 : e1700014 31 May 2017MATERIALS AND METHODS
System specifications
The initial structure of dasatinib bound to kinase was obtained from
PDB (PDB 3G5D). OPLS all-atom force field and TIP4P water models
were used. The full system, which consisted of 50,411 atoms, including
protein, solvent, and charge-compensating counterions, was prepared
and equilibrated using the exact same specifications as in the work of
Mondal et al. (34). We refer to this work in full detail. All our simula-
tionswere performedusing constant temperature and volume ensemble
at temperature T = 300 K using the software GROMACS 4.6.7 patched
with the plugin PLUMED 2.1.
We also repeated some of the calculations of this work using a
complete different force field and ligand charge parametrization to as-
certain the robustness of the results in a qualitative sense. For this, we
used the AMBER ff99SB*-ILDN force field to repeat three independent
unbinding runs with a frequent biasing protocol (bias every 0.5 ps; all
other biasing parameters are identical to other reports). The ligand
charges were parametrized using the general amber force field and
AM1-BCC charges.
Infrequent metadynamics
Here, we used the infrequent metadynamics approach (22, 23) to ob-
taining kinetic rate constants. This involves periodic biasing of a few
(typically one to three) CVs or order parameters to increase the prob-
ability of escape from metastable states where the system would ordi-
narily be trapped (20). If theseCVs demarcate all relevant stable states of
interest and if the time interval between biasing events is much longer
than the transition path time spent in the ephemeral transition state re-
gions, then the likelihood of not adding bias in the transition state (TS)
regions increases. This preserves the sequence of transitions between
stable states that the unbiased trajectorywould have taken (22). Further-
more, the acceleration a of transition rates through biasing, which di-
rectly yields the true unbiased rates, can be calculated through
generalized transition state theory (22, 45)
a ¼ 〈ebVðs;tÞ〉t ð1Þ
Here, s is the CV being biased, b = 1/kBT is the inverse temperature,
V (s, t) is the bias experienced at time t, and the subscript t indicates
averaging under the time-dependent potential. One can verify a poster-
iori whether the requirements in the work of Tiwary and Parnello (22)
and Salvalaglio (23) regarding quality of CVs and infrequency of bias
addition were satisfied by checking whether the cumulative distribution
function for the transition times from each stable state is Poissonian (23).
Two CVs were used in this work: the distance d of the drug to the
ligand and the solvation statew of the binding pocket. The distance var-
iable dwas taken as the center-of-mass distance between two of the hy-
drogen bond formers in the bound pose, namely, between the groups
Met77:O,Met77:N and ligand:N,ligand:N1. Because the CVs need to be
smoothly differentiable to be biased, the pocket solvation variablewwas






Here, set A denotes the protein atoms Thr74:Og1, Glu75:O, and
Asp140:Ca that comprise the core of the buried interactions that the pro-
tein makes with the drug in the bound pose. Set B comprises all the6 of 8
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 oxygen atoms of various water molecules. ri,j is the distance in nano-
meters between atoms i and j coming from these two sets, respectively.
The function
f rð Þ≡ ð1 ðr=0:6Þ
6Þ
ð1 ðr=0:6Þ10Þ ð3Þ
is a switching function that makes w smoothly differentiable.
The bias was added once every 8 ps as a bivariate Gaussian
function of the above-defined variables d and w, V d;wð Þ ¼
h0e
Vðdt ;wt ÞkBDT eðddtÞ
2=2s2dðwwtÞ2=2s2w .
Here, dt andwt are the values of the CVs at a certain time t, h0 is the
initial Gaussian amplitude, which we kept at 1.8 kJ/mol. DT, which we
acquired to be DT = 14T, is the so-called tempering parameter, which
smoothly modulates the amplitude of the Gaussian each time a certain
point in the CV space is revisited. The Gaussian widths sd and sw were
0.02 nmand 0.02U, respectively. The free energy as function of these two
variables, defined below, can be estimated from the bias as [within an ad-
ditive constant (21)]
F d;wð Þ ¼ kBT logP d;wð Þ ¼ T þ DTDT V d;wð Þ ð4Þ
where P(d, w) is the stationary probability density as a function of
d and w.
We defined the unbound state as states with d > 1.8 nm, beyond
whichwe find that the ligand diffuses either on the surface of the protein
or in the bulk. All 12 independent simulations were run until they gave
full unbinding. This took between 150 ns of unscaled MD time for the
fastest exit event and as much as 750 ns for the slowest event. Through
each of the simulations, we found no deterioration of the protein struc-
ture, as measured by the RMSD value of the heavy atoms, which stayed
within 3.5 Å of the native state.
SUPPLEMENTARY MATERIALS
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